Euroapi S.A. (OTCMKTS:EAPIF) Short Interest Update

Euroapi S.A. (OTCMKTS:EAPIF) was the target of a large drop in short interest in April. As of April 15th, there was short interest totaling 23,825 shares, a drop of 44.6% from the March 31st total of 42,983 shares. Based on an average daily volume of 1,287 shares, the days-to-cover ratio is currently 18.5 days.

Euroapi Stock Performance

EAPIF remained flat at C$1.55 during midday trading on Wednesday. 3,001 shares of the company’s stock traded hands, compared to its average volume of 1,575. Euroapi has a 52-week low of C$1.27 and a 52-week high of C$3.74. The firm has a fifty day moving average price of C$1.67 and a 200-day moving average price of C$2.59.

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Euroapi in a research report on Thursday, January 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Euroapi Company Profile

Euroapi is a standalone global active pharmaceutical ingredient (API) company formed in 2022 following its spin-off from the API division of a major multinational pharmaceutical group. The company focuses on the development, manufacturing and supply of a broad range of small-molecule APIs used in prescription drugs, over-the-counter products and vaccines. Its portfolio encompasses core areas such as semi-synthetic antibiotics (notably penicillins and cephalosporins), APIs for oncology, central nervous system disorders and cardiovascular therapies, as well as niche specialty ingredients.

Since its inception, Euroapi has pursued a growth strategy centered on innovation, capacity expansion and long-term partnerships with pharmaceutical customers.